CorMedix Inc. (CRMD)

Price$7.58

Favorite Metrics

Price vs S&P 500 (26W)-35.24%

Price vs S&P 500 (4W)9.93%

Market Capitalization$584.18M

P/E Ratio (Annual)3.58x

All Metrics

P/CF (Annual)3.34x

Book Value / Share (Quarterly)$5.11

P/TBV (Annual)34.93x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)1545.19%

Cash Flow / Share (Quarterly)$2.18

Price vs S&P 500 (YTD)-38.75%

Gross Margin (TTM)88.46%

Net Profit Margin (TTM)52.31%

EPS (TTM)$1.98

10-Day Avg Trading Volume0.95M

EPS Excl Extra (TTM)$1.98

Revenue Growth (5Y)319.48%

EPS (Annual)$2.03

ROI (Annual)29.59%

Gross Margin (Annual)88.46%

Net Profit Margin (5Y Avg)-13288.81%

Cash / Share (Quarterly)$1.87

P/E Basic Excl Extra (TTM)3.58x

Revenue Growth QoQ (YoY)312.10%

P/E Normalized (Annual)3.58x

ROA (Last FY)19.74%

Revenue Growth TTM (YoY)617.03%

EBITD / Share (TTM)$1.80

ROE (5Y Avg)-29.17%

Operating Margin (TTM)48.17%

Cash Flow / Share (Annual)$2.18

P/B Ratio1.44x

P/B Ratio (Quarterly)2.26x

Net Income / Employee (Annual)$1

EV / Revenue (TTM)1.88x

Net Interest Coverage (TTM)-1472.00x

ROA (TTM)32.95%

EPS Growth QoQ (YoY)-31.99%

EV / EBITDA (TTM)4.05x

EPS Incl Extra (Annual)$2.03

Current Ratio (Annual)2.11x

Quick Ratio (Quarterly)1.87x

3-Month Avg Trading Volume2.33M

52-Week Price Return-1.17%

EV / Free Cash Flow (Annual)3.39x

P/E Incl Extra (TTM)3.58x

Revenue / Employee (TTM)$2

Tangible BV / Share (Quarterly)$0.33

P/S Ratio (Annual)1.87x

Asset Turnover (Annual)0.38x

52-Week High$17.43

Operating Margin (5Y Avg)-14116.51%

EPS Excl Extra (Annual)$2.03

CapEx CAGR (5Y)83.04%

Tangible BV CAGR (5Y)50.24%

26-Week Price Return-28.36%

Quick Ratio (Annual)1.87x

13-Week Price Return8.13%

Total Debt / Equity (Annual)0.36x

Current Ratio (Quarterly)2.11x

Enterprise Value$585.153

Revenue / Share Growth (5Y)241.15%

Asset Turnover (TTM)0.63x

Book Value / Share Growth (5Y)31.16%

Revenue / Employee (Annual)$2

Inventory Turnover (Annual)1.93x

Pretax Margin (Annual)48.13%

Cash / Share (Annual)$1.87

3-Month Return Std Dev46.63%

Gross Margin (5Y Avg)60.08%

Net Income / Employee (TTM)$1

ROE (Last FY)40.23%

Net Interest Coverage (Annual)-749.50x

EPS Basic Excl Extra (Annual)$2.03

P/FCF (TTM)3.38x

Receivables Turnover (TTM)2.80x

EV / Free Cash Flow (TTM)3.39x

Total Debt / Equity (Quarterly)0.36x

EPS Incl Extra (TTM)$1.98

Receivables Turnover (Annual)2.80x

ROI (TTM)46.37%

P/S Ratio (TTM)1.87x

Pretax Margin (5Y Avg)-14021.27%

Revenue / Share (Annual)$3.88

Tangible BV / Share (Annual)$0.33

Forward P/E11.48x

Price vs S&P 500 (52W)-35.81%

P/E Ratio (TTM)3.58x

Year-to-Date Return-34.82%

5-Day Price Return3.84%

EPS Normalized (Annual)$2.03

ROA (5Y Avg)-28.12%

Net Profit Margin (Annual)52.31%

Month-to-Date Return11.63%

Cash Flow / Share (TTM)$-0.85

EBITD / Share (Annual)$1.80

Operating Margin (Annual)48.17%

LT Debt / Equity (Annual)0.36x

P/CF (TTM)3.34x

ROI (5Y Avg)-31.30%

P/E Excl Extra (TTM)3.58x

LT Debt / Equity (Quarterly)0.36x

EPS Basic Excl Extra (TTM)$1.98

P/TBV (Quarterly)34.93x

P/B Ratio (Annual)2.26x

Inventory Turnover (TTM)1.93x

Pretax Margin (TTM)48.13%

Book Value / Share (Annual)$5.11

Price vs S&P 500 (13W)5.75%

Beta1.49x

P/FCF (Annual)3.38x

Revenue / Share (TTM)$3.31

ROE (TTM)58.50%

52-Week Low$6.13

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.15

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CRMDCorMedix Inc.	1.87x	617.03%	88.46%	—	$7.58
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.69
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.87x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

Cormedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases. The company's primary product, DefenCath, is being marketed in the United States and other key markets.